PDCD1 and non-small cell lung carcinoma: In terms of the label-independent isolation methods, PD-L1+ CTCs isolated by Parsortix were detected in 20% of advanced NSCLC patients before anti-PD-1 treatment [11], in 35% of advanced NSCLC patients undergoing pembrolizumab therapy [12] and in 56% of NSCLC patients’ samples [13].